

October 20, 1968

Dr. Peter Siegler  
National Drug Co.  
Philadelphia, Pa.

Dear Dr. Siegler,

I have read the descriptive material of aletamine (NDR 5061A) with considerable interest. It is probable that we are able to contribute to the evaluation of this compound and I would like to ask you to visit my laboratory on the occasion of your next visit to New York to discuss this further.

I am taking the liberty of enclosing a discussion from this laboratory which was presented at the recent meeting on thioxanthenes sponsored by the Quebec Psychopharmacological Association. It will present our point of view and suggest some methods which may be useful with aletamine.

Thank you for your interest.

Sincerely yours,

Max Pink, M.D.  
Professor of Psychiatry

mf-